India just got its first weapon against a disease that infects millions every monsoon.
QDENGA, made by Japan's Takeda, has been cleared by India's drug regulator for anyone aged 4 to 60.
No prior testing needed.
No screening for past infection.
Just two shots, three months apart.
Here's why that detail matters more than it sounds.
Dengue isn't one virus. It's four serotypes hiding under one name.
Get infected by one, survive it, then catch a different serotype later — and your second infection can turn severe. Sometimes fatal.
That's what made vaccine-making so brutal here.
Most shots protect against a couple of strains.
QDENGA claims all four.
And unlike an earlier dengue vaccine that got pulled back over safety concerns in people with no prior exposure, this one doesn't require a blood test before you roll up your sleeve.
This isn't Takeda testing the waters.
Seven years of follow-up data already show the protection holds up — against infection and hospitalization.
Takeda isn't just shipping vials in.
It's partnered with Hyderabad-based Biological E to manufacture locally, with plans to scale toward 100 million doses a year within a decade.
Translation: this isn't a one-time import story. It's infrastructure being built for a disease that isn't going away.
Private hospitals are expected to stock it later this year.
Pricing? Still being worked out — Takeda says it'll use a tiered model so it isn't priced only for the few.
A vaccine alone won't kill dengue.
Standing water, poor drainage, mosquito breeding — those fights continue.
But for the first time, India has a shot — literally — that doesn't ask "were you infected before?"
It just asks you to show up twice.
That's all for now!
